Recent News for TSHA - Taysha Gene Therapies, Inc.

Date Title
Mar 3 Taysha Gene Therapies Reports Full-Year 2020 Financial Results and Provides a Corporate Update
Mar 3 Taysha Gene Therapies Inc to Host Earnings Call
Mar 2 Earnings Scheduled For March 2, 2021
Mar 1 Taysha Gene Therapies to Release Full-Year 2020 Financial Results and Host Conference Call and Webcast on March 3
Feb 26 Taysha Gene Therapies Announces Support of Rare Disease Day 2021
Feb 16 Taysha Gene Therapies Announces Formation of Independent Scientific Advisory Board
Feb 10 Taysha Gene Therapies Announces Participation in Upcoming Investor Healthcare Conferences
Feb 9 Taysha Gene Therapies Announces Collaborations to Advance Next-Generation Mini-Gene Payloads for AAV Gene Therapies for the Treatment of Genetic Epilepsies and Additional CNS Disorders
Feb 1 Taysha Gene Therapies Highlights Strategic Priorities and Provides 2021 Business Outlook
Jan 26 Taysha Gene Therapies Continues to Add Significant Gene Therapy Expertise to Leadership Team with the Appointment of Chief Legal Officer and Chief People Officer
Jan 20 The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study
Jan 19 Taysha Gene Therapies granted Orphan Drug designation for TSHA-105
Jan 19 Taysha Gene Therapies Receives Rare Pediatric Disease and Orphan Drug Designations for TSHA-105 for the Treatment of Epilepsy Caused by SLC13A5 Deficiency
Jan 15 The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges
Jan 13 Taysha and UT Southwestern Medical Center launch innovation fund in gene therapy development push
Jan 13 Taysha Gene Therapies and UT Southwestern Medical Center Launch Innovation Fund to Accelerate Advancement of AAV Gene Therapies for Monogenic Diseases of the Central Nervous System
Jan 4 Taysha teams up with AllStripes to advance gene therapy for rare disorder
Jan 4 Taysha Gene Therapies Announces Collaboration with AllStripes on SURF1-Associated Leigh Syndrome Clinical Development and Natural History
Dec 29 Taysha Gene Therapies Expands Leadership Team to Deepen Manufacturing and Communications Capabilities
Dec 24 What You Need To Know About Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) Investor Composition
Dec 21 Taysha on go with early-stage study with its gene therapy in inherited lysosomal storage disorder
Dec 21 Taysha Gene Therapies Announces Queen’s University’s Receipt of Clinical Trial Application Approval from Health Canada for Phase 1/2 Clinical Trial of TSHA-101 for the Treatment of Infantile GM2 Gangliosidosis
Dec 17 Taysha Gene Therapies Announces New cGMP Gene Therapy Manufacturing Facility
Dec 17 Is TSHA A Good Stock To Buy Now?
Dec 15 Taysha Gene Therapies Set to Join Russell 2000® Index on December 21, 2020
Back to the Main TSHA Page...